IMMUNE PROFILING TO INVESTIGATE IMPROVED SURVIVAL IN PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER RECEIVING TRILACICLIB PRIOR TO CHEMOTHERAPY

被引：1
|
作者：
Stevens, Aaron [1 ]
O'Shaughnessy, Joyce [2 ]
Cao, Subing [1 ]
Sorrentino, Jessica [1 ]
Horton, Janet [1 ]
Yi, John [1 ]
Tan, Antoinette [3 ]
机构：
[1] G1 Therapeutics Inc, Res Triangle Pk, NC USA
[2] Baylor Univ, Med Ctr, Texas Oncol Dallas, US Oncol Res, Dallas, TX USA
[3] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷
关键词：
D O I：
10.1136/jitc-2021-SITC2021.339
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
339
引用
收藏
页码：A365 / A365
页数：1
相关论文
共 50 条
  • [1] Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer
    Antoinette R. Tan
    Joyce O’Shaughnessy
    Subing Cao
    Sarah Ahn
    John S. Yi
    Breast Cancer Research and Treatment, 2023, 201 : 307 - 316
  • [2] Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer
    Tan, Antoinette R.
    O'Shaughnessy, Joyce
    Cao, Subing
    Ahn, Sarah
    Yi, John S.
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 201 (02) : 307 - 316
  • [3] Patients with metastatic triple-negative breast cancer who receive trilaciclib prior to cytotoxic chemotherapy exhibit improved survival after receiving subsequent anticancer therapy
    Goel, Shom
    O'Shaughnessy, Joyce
    Lu, Kun-Hui
    Beelen, Andrew
    Melemed, Symantha
    Yi, John
    Danso, Michael
    Tan, Antoinette
    CANCER RESEARCH, 2024, 84 (09)
  • [4] Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study
    Tan, Antoinette R.
    Wright, Gail S.
    Thummala, Anu R.
    Danso, Michael A.
    Popovic, Lazar
    Pluard, Timothy J.
    Han, Hyo S.
    Vojnovic, Zeljko
    Vasev, Nikola
    Ma, Ling
    Richards, Donald A.
    Wilks, Sharon T.
    Milenkovic, Dusan
    Xiao, Jie
    Sorrentino, Jessica
    Horton, Janet
    O'Shaughnessy, Joyce
    CLINICAL CANCER RESEARCH, 2022, 28 (04) : 629 - 636
  • [5] Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2
    Goel, Shom
    Tan, Antoinette R.
    Rugo, Hope S.
    Aftimos, Philippe
    Andric, Zoran
    Beelen, Andrew
    Zhang, Jingshan
    Yi, John S.
    Malik, Rajesh
    O'Shaughnessy, Joyce
    FUTURE ONCOLOGY, 2022, 18 (33) : 3701 - 3711
  • [6] Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit
    Barroso-Sousa, Romualdo
    Forman, Juliet
    Collier, Katharine
    Weber, Zachary T.
    Jammihal, Tejas R.
    Kao, Katrina Z.
    Richardson, Edward T., III
    Keenan, Tanya
    Cohen, Ofir
    Manos, Michael P.
    Brennick, Ryan C.
    Ott, Patrick A.
    Hodi, F. Stephen
    Dillon, Deborah A.
    Attaya, Victoria
    O'Meara, Tess
    Lin, Nancy U.
    Van Allen, Eliezer M.
    Rodig, Scott
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Wu, Catherine J.
    Wagle, Nikhil
    Stover, Daniel G.
    Shukla, Sachet A.
    Tolaney, Sara M.
    JCO PRECISION ONCOLOGY, 2022, 6
  • [7] Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial
    Tan, Antoinette R.
    Wright, Gail S.
    Thummala, Anu R.
    Danso, Michael A.
    Popovic, Lazar
    Pluard, Timothy J.
    Han, Hyo S.
    Vojnovic, Zeljko
    Vasev, Nikola
    Ma, Ling
    Richards, Donald A.
    Wilks, Sharon T.
    Milenkovic, Dusan
    Yang, Zhao
    Antal, Joyce M.
    Morris, Shannon R.
    O'Shaughnessy, Joyce
    LANCET ONCOLOGY, 2019, 20 (11): : 1587 - 1601
  • [8] Prognostic Factors for Triple-Negative Breast Cancer Patients Receiving Preoperative Systemic Chemotherapy
    Asaga, Sota
    Kinoshita, Takayuki
    Hojo, Takashi
    Suzuki, Junko
    Jimbo, Kenjiro
    Tsuda, Hitoshi
    CLINICAL BREAST CANCER, 2013, 13 (01) : 40 - 46
  • [9] Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy
    Oonk, A. M. M.
    van Rijn, C.
    Smits, M. M.
    Mulder, L.
    Laddach, N.
    Savola, S. P.
    Wesseling, J.
    Rodenhuis, S.
    Imholz, A. L. T.
    Lips, E. H.
    ANNALS OF ONCOLOGY, 2012, 23 (09) : 2301 - 2305
  • [10] Metastatic Triple-negative Breast Cancer
    Rakha, E. A.
    Chan, S.
    CLINICAL ONCOLOGY, 2011, 23 (09) : 587 - 600
12345